Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation

3 Months Ended

Mar. 31, 2023

Note 12 — Share-based compensation

The share-based compensation expense decrease is driven largely by additional forefeitures of $1,796,500 in the quarter as a result of the recent restructuring. The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended
		March 31,
	2023		2022
Research and development	$	116	$	2,523
General and administrative		1,560		3,063
	$	1,676	$	5,586

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended
		March 31,
	2023		2022
Number of options over ordinary shares granted		21,755,328		22,876,464
Weighted average fair value of ordinary shares options	$	0.25	$	0.43
Number of additional options with a nominal exercise price granted		19,866,912		17,688,432
Weighted average fair value of options with a nominal exercise price	$	0.32	$	0.59